Scott Huntington
Research & Publications
Biography
News
Research Summary
With the rapid evolution of cancer diagnostics and therapeutics, cancer care is increasingly complex. Dr. Huntington draws from his unique combination of clinical and health services research training to lead studies that aim to establish an evidence base enabling high quality patient-centered care. His research has leveraged large real-world data, patient-reported outcomes, and economic modeling to address critical questions facing patients with hematologic malignancies.
In addition to his health services research, Dr. Huntington is a dedicated clinical investigator focused on bringing novel therapeutics and innovative clinical trials to patients with lymphoma treated across the Smilow Cancer Center network.
Coauthors
Research Interests
Hematologic Diseases; Insurance; Lymphoma
Public Health Interests
Health Insurance
Selected Publications
- Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphomaPotnis K, Huntington S. Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma. Blood Advances 2023, 7: 2573-2574. PMID: 36745098, PMCID: PMC10242627, DOI: 10.1182/bloodadvances.2023009864.
- Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort.Bowers J, Anna J, Bair S, Annunzio K, Epperla N, Joy Pullukkara J, Gaballa S, Spinner M, Li S, Messmer M, Nguyen J, Ayers E, Wagner C, Hu B, Di M, Huntington S, Furqan F, Shah N, Chen C, Svoboda J. Brentuximab vedotin + AVD for newly diagnosed classic Hodgkin lymphoma (cHL): Incidence and management of peripheral neuropathy in a multi-institution cohort. Journal Of Clinical Oncology 2023, 41: 7542-7542. DOI: 10.1200/jco.2023.41.16_suppl.7542.
- The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021Goyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. The COVID-19 Pandemic and In-Person Visit Rate Disruptions Among Patients With Hematologic Neoplasms in the US in 2020 to 2021. JAMA Network Open 2023, 6: e2316642. PMID: 37273206, PMCID: PMC10242428, DOI: 10.1001/jamanetworkopen.2023.16642.
- A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL).Olszewski A, Huntington S, Ollila T, Pelcovits A, McMahon J, Yakirevich I, Sturtevant A, Chorzalska A, Morgan J, Dubielecka P. A phase 2 trial of mosunetuzumab with lenalidomide augmentation as first-line therapy for follicular (FL) and marginal zone lymphoma (MZL). Journal Of Clinical Oncology 2023, 41: tps7588-tps7588. DOI: 10.1200/jco.2023.41.16_suppl.tps7588.
- Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future?Bewersdorf J, Huntington S, Zeidan A. Cost-Effectiveness Analyses in AML: What Have We Learned, How Should This Impact Patient Care, and What Needs to Be Done in the Future? Journal Of The National Comprehensive Cancer Network 2023, 21: 522-528. PMID: 37037494, DOI: 10.6004/jnccn.2023.70012.
- Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherenceShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Stempel J, Mendez L, Di M, Ma X, Podoltsev N. Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence. Blood Advances 2023 PMID: 36939371, DOI: 10.1182/bloodadvances.2022009074.
- DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b studyHuntington S, Schuster S, Ding W, Koehler A, Brander D, Rosenthal A, Leis J, Tun H, Moustafa M, Iqbal M, He W, Kearney A, McKinlay T, Gui M, Mato A. DTRMWXHS‐12, a novel Bruton tyrosine kinase inhibitor, in combination with everolimus and pomalidomide in patients with relapsed/refractory lymphomas: An open‐label, multicenter, phase 1a/1b study. American Journal Of Hematology 2023, 98: 739-749. PMID: 36810799, DOI: 10.1002/ajh.26888.
- Functional status and therapy for older adults with diffuse large B‐cell lymphoma in nursing homes: A population‐based studyDi M, Keeney T, Belanger E, Huntington S, Olszewski A, Panagiotou O. Functional status and therapy for older adults with diffuse large B‐cell lymphoma in nursing homes: A population‐based study. Journal Of The American Geriatrics Society 2023 PMID: 36882865, DOI: 10.1111/jgs.18302.
- Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular LymphomaPotnis K, Di M, Isufi I, Gowda L, Seropian S, Foss F, Forman H, Huntington S. Cost-Effectiveness of Chimeric Antigen Receptor T-Cell Therapy in Adults with Relapsed or Refractory Follicular Lymphoma. Blood Advances 2023, 7: 801-810. PMID: 36342852, PMCID: PMC10011202, DOI: 10.1182/bloodadvances.2022008097.
- Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis.Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis. Haematologica 2023 PMID: 36655436, DOI: 10.3324/haematol.2022.282252.
- Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemiaBewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stein E, Huntington S, Zeidan A. Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia. Leukemia & Lymphoma 2022, 64: 454-461. PMID: 36493798, PMCID: PMC9957935, DOI: 10.1080/10428194.2022.2140288.
- Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid LeukemiaBewersdorf J, Patel K, Goshua G, Shallis R, Podoltsev N, Stahl M, Stempel J, Stein E, Huntington S, Zeidan A. Cost-Effectiveness of Azacitidine and Ivosidenib in Newly Diagnosed Older, Intensive Chemotherapy-Ineligible Patients with IDH1 -Mutant Acute Myeloid Leukemia. Blood 2022, 140: 319-321. DOI: 10.1182/blood-2022-158465.
- Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based AnalysisDi M, Long J, Isufi I, Foss F, Seropian S, Gross C, Huntington S. Total Costs of Care during Chimeric Antigen Receptor T-Cell Therapy in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma: A Large Private Insurance Claim-Based Analysis. Blood 2022, 140: 10818-10819. DOI: 10.1182/blood-2022-164915.
- Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based AnalysisDi M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Stempel J, Ma X, Huntington S. Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis. Blood 2022, 140: 10904-10906. DOI: 10.1182/blood-2022-164959.
- Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with RuxolitinibStempel J, Wang R, Shallis R, Huntington S, Zeidan A, Neparidze N, Di M, Ma X, Podoltsev N. Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib. Blood 2022, 140: 11004-11006. DOI: 10.1182/blood-2022-165156.
- Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)Olszewski A, Huntington S, Bannerji R, Ollila T, McMahon J, Dubielecka P. Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL). Blood 2022, 140: 6492-6493. DOI: 10.1182/blood-2022-157463.
- Treatment Patterns of Follicular Lymphoma in the United States: A Claims AnalysisHuntington S, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. Journal Of Health Economics And Outcomes Research 2022, 9: 115-122. PMID: 36348725, PMCID: PMC9603402, DOI: 10.36469/001c.38070.
- Treatment Patterns of Follicular Lymphoma in the United States: A Claims AnalysisHuntington S, Appukkuttan S, Wang W, Du Y, Hopson S, Babajanyan S. Treatment Patterns of Follicular Lymphoma in the United States: A Claims Analysis. Journal Of Health Economics And Outcomes Research 2022, 115-122. DOI: 10.36469/jheor.2022.38070.
- Poster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic LeukemiaHuntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Fuldeore M, Doshi J. Poster: CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s143. DOI: 10.1016/s2152-2650(22)00867-9.
- CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic LeukemiaHuntington S, Manzoor B, Puckett J, Kamal-Bahl S, Alhasani H, Ravelo A, Fuldeore M, Doshi J. CLL-410 Adherence and Discontinuation Among Medicare Beneficiaries Initiating Venetoclax versus BTKis for Relapsed/Refractory Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma & Leukemia 2022, 22: s277-s278. DOI: 10.1016/s2152-2650(22)01345-3.
- Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses.Di M, Long J, Kothari S, Sethi T, Zeidan A, Podoltsev N, Shallis R, Wang R, Ma X, Huntington S. Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: A population-based analyses. Journal Of Clinical Oncology 2022, 40: 7554-7554. DOI: 10.1200/jco.2022.40.16_suppl.7554.
- Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525)Odejide O, Huntington S, Hurley S, Kaufman R, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Transfusion Access and Hospice Among Patients with Advanced Hematologic Malignancies (RP525). Journal Of Pain And Symptom Management 2022, 63: 1111-1112. DOI: 10.1016/j.jpainsymman.2022.04.091.
- 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous LeukemiaMirza A, Byrne M, Huntington S, Shallis R, Zeidan A, Foss F, Isufi I, Podoltsev N, Engelhardt B, Kassim A, Savani B, Dholaria B, Jayani R, Perrault S, Schiffer M, Seropian S, Gowda L. 168 Impact of Post-Remission Consolidation Therapy on Outcomes of Haploidentical Hematopoietic Cell Transplantation for Acute Myelogenous Leukemia. Transplantation And Cellular Therapy 2022, 28: s139-s140. DOI: 10.1016/s2666-6367(22)00329-3.
- Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutionsOrellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, Watkins M, Kahl BS, Spinner MA, Advani R, Voorhees TJ, Snow A, Grover NS, Ayers A, Romancik J, Liu Y, Huntington SF, Chavez JC, Saeed H, Lazaryan A, Raghunathan V, Spurgeon SE, Ollila TA, Del Prete C, Olszewski A, Ayers EC, Landsburg DJ, Echalier B, Lee J, Kamdar M, Caimi PF, Fu T, Liu J, David KA, Alharthy H, Law J, Karmali R, Shah H, Stephens DM, Major A, Rojek AE, Smith SM, Yellala A, Kallam A, Nakhoda S, Khan N, Sohail MA, Hill BT, Barrett-Campbell O, Lansigan F, Switchenko J, Cohen J, Portell CA. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions. Blood 2022, 139: 413-423. PMID: 34570876, PMCID: PMC8777199, DOI: 10.1182/blood.2021012888.
- Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United StatesBewersdorf JP, Prozora S, Podoltsev NA, Shallis RM, Huntington SF, Neparidze N, Wang R, Zeidan AM, Davidoff AJ. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia in the United States. Blood Advances 2022, 6: 376-385. PMID: 34724703, PMCID: PMC8791583, DOI: 10.1182/bloodadvances.2021005642.
- Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020Huntington SF, Ingham MP, Okonkwo L, Singh A, Wang R, Ammann EM. Treatment patterns, economic burden, and overall survival in US Medicare Advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020. Leukemia & Lymphoma 2021, 63: 1180-1190. PMID: 34913805, DOI: 10.1080/10428194.2021.2012666.
- Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemiaBewersdorf JP, Patel K, Huntington SF, Zeidan AM. Cost-effectiveness analysis of oral azacitidine maintenance therapy in acute myeloid leukemia. Blood Advances 2021, 5: 4686-4690. PMID: 34525174, PMCID: PMC8759135, DOI: 10.1182/bloodadvances.2021005472.
- Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid LeukemiaBewersdorf J, Goshua G, Patel K, Shallis R, Podoltsev N, Huntington S, Zeidan A. Cost-Effectiveness of Liposomal Cytarabine-Daunorubicin (CPX-351) Compared to Conventional Cytarabine-Daunorubicin Chemotherapy in Acute Myeloid Leukemia. Blood 2021, 138: 113-113. DOI: 10.1182/blood-2021-144992.
- Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based AnalysisDi M, Cui C, Kothari S, Zeidan A, Podoltsev N, Neparidze N, Shallis R, Wang R, Ma X, Huntington S. Survival of Mantle Cell Lymphoma in the Era of Bruton Tyrosine Kinase Inhibitors: A Population-Based Analysis. Blood 2021, 138: 182-182. DOI: 10.1182/blood-2021-146417.
- Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic PeriodNeparidze N, Wang R, Zeidan A, Podoltsev N, Shallis R, Ma X, Davidoff A, Huntington S. Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period. Blood 2021, 138: 4092-4092. PMCID: PMC8701553, DOI: 10.1182/blood-2021-148998.
- Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United StatesShallis R, Wang R, Zeidan A, Huntington S, Neparidze N, Di M, Ma X, Podoltsev N. Contemporary "Real World" Molecular Testing and Tyrosine Kinase Inhibitor Adherence Patterns Among Older Pts with Chronic Myeloid Leukemia in the United States. Blood 2021, 138: 282-282. DOI: 10.1182/blood-2021-151066.
- Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United StatesGoyal G, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Neparidze N, Seymour E. Impact of the COVID-19 Pandemic on in-Person Visit Rates Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1930-1930. PMCID: PMC8701834, DOI: 10.1182/blood-2021-153625.
- Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United StatesNeparidze N, Lau K, Wang X, Davidoff A, Huntington S, Jamy O, Calip G, Shah H, Stephens D, Miksad R, Parikh R, Takvorian S, Goyal G, Seymour E. Racial Disparities in Telemedicine Uptake during the COVID-19 Pandemic Among Patients with Hematologic Malignancies in the United States. Blood 2021, 138: 1973-1973. PMCID: PMC8701527, DOI: 10.1182/blood-2021-153787.
- Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL StudyJacobs R, Jurczak W, Flinn I, Grosicki S, Giannopoulos K, Wróbel T, Zafar S, Cultrera J, Kambhampati S, Danilov A, Burke J, Goldschmidt J, Beach D, Huntington S, Pinilla Ibarz J, Sharman J, Siddiqi T, Brander D, Shadman M, Pagel J, Dlugosz-Danecka M, Ghosh N, Kolibaba K, Sportelli P, Miskin H, O'Connor O, Weiss M, Gribben J. Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study. Blood 2021, 138: 3726-3726. DOI: 10.1182/blood-2021-147460.
- First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with HclPark J, Winer E, Huntington S, von Keudell G, Vemuri S, Shukla M, Kinoshita J, Falco V, Gore S, Stone R, Abdel-Wahab O, Tallman M. First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl. Blood 2021, 138: 43-43. DOI: 10.1182/blood-2021-151074.
- Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 TrialPinilla Ibarz J, Jurczak W, Kambhampati S, Lech Maranda E, Wróbel T, Sharman J, Zafar S, Hoffmann M, Huntington S, Jacobs R, Bairey O, Rowland C, Miskin H, Sportelli P, Weiss M, O'Connor O, Flinn I. Favorable Outcomes for Patients Treated with U2 with Co-Morbidities or Concomitant Medications: A Retrospective Analysis of Unity-CLL Phase 3 Trial. Blood 2021, 138: 3748-3748. DOI: 10.1182/blood-2021-151292.
- Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling SurveyOdejide O, Huntington S, Shi E, Johnson K, Tulsky J, Abel G. Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey. Blood 2021, 138: 3020-3020. DOI: 10.1182/blood-2021-153304.
- Perceptions of Prognosis Among Patients with Advanced Hematologic MalignanciesOdejide O, Huntington S, Kuczmarski T, Shi E, Tulsky J, Abel G. Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies. Blood 2021, 138: 4026-4026. DOI: 10.1182/blood-2021-153361.
- Primary anti-infective prophylaxis during routine treatment of lymphoma in the United States: A large real-world cohort analysis.Di M, Soulos P, Huntington S. Primary anti-infective prophylaxis during routine treatment of lymphoma in the United States: A large real-world cohort analysis. Journal Of Clinical Oncology 2021, 39: 268-268. DOI: 10.1200/jco.2020.39.28_suppl.268.
- COVID-19 in patients with CLL: improved survival outcomes and update on management strategiesRoeker LE, Eyre TA, Thompson MC, Lamanna N, Coltoff AR, Davids MS, Baker PO, Leslie L, Rogers KA, Allan JN, Cordoba R, Lopez-Garcia A, Antic D, Pagel JM, Martinez-Calle N, García-Marco JA, Hernández-Rivas JÁ, Miras F, Coombs CC, Österborg A, Hansson L, Seddon AN, López Jiménez J, Wilson MR, El-Sharkawi D, Wojenski D, Ma S, Munir T, Valenciano S, Seymour E, Barr PM, Pu J, Patten PEM, Perini GF, Huntington SF, Parry H, Sundaram S, Skarbnik A, Kamdar M, Jacobs R, Walter H, Walewska R, Broom A, Lebowitz S, Isaac KM, Portell CA, Ahn IE, Ujjani CS, Shadman M, Skånland SS, Chong EA, Mato AR. COVID-19 in patients with CLL: improved survival outcomes and update on management strategies. Blood 2021, 138: 1768-1773. PMID: 34297826, PMCID: PMC8313815, DOI: 10.1182/blood.2021011841.
- Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myelomaPatel KK, Parker T, Di M, Bar N, Huntington SF, Giri S. Cost-effectiveness of once-weekly selinexor, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma. Leukemia & Lymphoma 2021, 62: 2777-2784. PMID: 34151696, DOI: 10.1080/10428194.2021.1933477.
- Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database.Jin Y, Li J, Mun Y, Masaquel A, Hu S, Biondo J, Huntington S. Racial, ethnic, and socioeconomic disparities in treatment outcomes in patients (pts) with diffuse large B-cell lymphoma (DLBCL): A U.S. real-world study using a de-identified electronic health record (EHR)-derived database. Journal Of Clinical Oncology 2021, 39: e18514-e18514. DOI: 10.1200/jco.2021.39.15_suppl.e18514.
- Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model.Yue A, Chaudhry B, Schleicher S, Huntington S, Lyss A, Connor N, Tran L, Adelson K. Bundling cancer subtypes in value-based care: A pilot analysis of lymphoma episodes in the Oncology Care Model. Journal Of Clinical Oncology 2021, 39: e18850-e18850. DOI: 10.1200/jco.2021.39.15_suppl.e18850.
- Overall survival based on oncologist density in the United States: A retrospective cohort studyMalleshappa S, Giri S, Patel S, Mehta T, Appleman L, Huntington SF, Passero V, Parikh RA, Mehta KD. Overall survival based on oncologist density in the United States: A retrospective cohort study. PLOS ONE 2021, 16: e0250894. PMID: 33979399, PMCID: PMC8115849, DOI: 10.1371/journal.pone.0250894.
- Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United StatesWang X, Zeidan AM, Wang R, Bewersdorf JP, Zhang C, Podoltsev NA, Huntington SF, Gore SD, Ma X. Clinical effectiveness of DNA methyltransferase inhibitors and lenalidomide in older patients with refractory anemia with ring sideroblasts: a population-based study in the United States. Leukemia & Lymphoma 2021, 62: 2438-2447. PMID: 33899659, DOI: 10.1080/10428194.2021.1913142.
- Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusionPerreault S, Schiffer M, Clinchy-Jarmoszko V, Bocchetta N, Barbarotta L, Abdelghany O, Foss F, Huntington S, Seropian S, Isufi I. Mitigating the risk of COVID-19 exposure by transitioning from clinic-based to home-based immune globulin infusion. American Journal Of Health-System Pharmacy 2021, 78: zxab072. PMID: 33617630, PMCID: PMC7929449, DOI: 10.1093/ajhp/zxab072.
- Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemiaPatel KK, Zeidan AM, Shallis RM, Prebet T, Podoltsev N, Huntington SF. Cost-effectiveness of azacitidine and venetoclax in unfit patients with previously untreated acute myeloid leukemia. Blood Advances 2021, 5: 994-1002. PMID: 33591323, PMCID: PMC7903235, DOI: 10.1182/bloodadvances.2020003902.
- Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma.Patel KK, Giri S, Parker TL, Bar N, Neparidze N, Huntington SF. Cost-Effectiveness of First-Line Versus Second-Line Use of Daratumumab in Older, Transplant-Ineligible Patients With Multiple Myeloma. Journal Of Clinical Oncology 2021, 39: 1119-1128. PMID: 33411586, DOI: 10.1200/jco.20.01849.
- Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal CancerPatel KK, Stein S, Lacy J, O’Hara M, Huntington SF. Evaluation of the Cost-effectiveness of Doublet Therapy in Metastatic BRAF Variant Colorectal Cancer. JAMA Network Open 2021, 4: e2033441. PMID: 33433598, PMCID: PMC7804917, DOI: 10.1001/jamanetworkopen.2020.33441.
- B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphomaKing ALO, Mirza FN, Lewis JM, Carlson KR, Huntington S, Foss FM, Girardi M. B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma. JAAD Case Reports 2020, 8: 89-92. PMID: 33537387, PMCID: PMC7838714, DOI: 10.1016/j.jdcr.2020.12.025.
- Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older PatientsDi M, Huntington SF, Olszewski AJ. Challenges and Opportunities in the Management of Diffuse Large B‐Cell Lymphoma in Older Patients. The Oncologist 2020, 26: 120-132. PMID: 33230948, PMCID: PMC7873335, DOI: 10.1002/onco.13610.
- Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple MyelomaPatel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.
- Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic LeukemiaBewersdorf J, Prozora S, Wang R, Podoltsev N, Shallis R, Huntington S, Neparidze N, Ma X, Gore S, Zeidan A, Davidoff A. Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-136983.
- Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesWang R, Shallis R, Bewersdorf J, Zeidan A, Huntington S, Ma X, Podoltsev N. Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood 2020, 136: 13-14. DOI: 10.1182/blood-2020-139468.
- Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United StatesShallis R, Wang R, Bewersdorf J, Zeidan A, Huntington S, Davidoff A, Ma X, Podoltsev N. Contemporary Practice Patterns of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States. Blood 2020, 136: 44-45. DOI: 10.1182/blood-2020-139531.
- Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and OutcomesDavidoff A, Long J, Neparidze N, Bewersdorf J, Shallis R, Podoltsev N, Wang R, Gore S, Zeidan A, Huntington S. Oncologist Sub-Specialization, Care Setting, and Multiple Myeloma Treatment and Outcomes. Blood 2020, 136: 2-3. DOI: 10.1182/blood-2020-140728.
- Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell LymphomasLee M, Schiffer M, Isufi I, Huntington S, Xu M, Seropian S, Gowda L, Kothari S, Girardi M, Foss F. Weekly Dosing Schedule of Brentuximab Vedotin in Mycosis Fungoides/Sezary Syndrome and Aggressive T Cell Lymphomas. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-139790.
- Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL)Hooley I, Maignan K, Jacob A, Medina A, Benderoff L, Chen R, Huntington S. Real-World IgG Testing Frequency and Characteristics Associated with Hypogammaglobulinemia after Anti-CD20 Exposure in Patients with Chronic Lymphocytic Leukemia (CLL). Blood 2020, 136: 43-44. DOI: 10.1182/blood-2020-137094.
- A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell LymphomaMato A, Schuster S, Foss F, Isufi I, Kothari S, Ding W, Brander D, Sitlinger A, Rosenthal A, Leis J, Tun H, Kennard K, Nelson A, Falco V, Komari C, Koehler A, Stowe R, He W, Kearney A, Gui M, McKinlay T, Roeker L, Thompson M, Huntington S. A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma. Blood 2020, 136: 21-22. DOI: 10.1182/blood-2020-138896.
- Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL StudyGribben J, Jurczak W, Jacobs R, Grosicki S, Giannopoulos K, Wrobel T, Zafar S, Cultrera J, Kambhampati S, Danilov A, Burke J, Goldschmidt J, Beach D, Huntington S, Pinilla Ibarz J, Sharman J, Siddiqi T, Brander D, Pagel J, Kolibaba K, Dlugosz-Danecka M, Ghosh N, Sportelli P, Miskin H, O'Connor O, Weiss M, Flinn I. Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. Blood 2020, 136: 37-39. DOI: 10.1182/blood-2020-134783.
- CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic InstitutionsOrellana-Noia V, Reed D, Sen J, Barlow C, Malecek M, Kahl B, Spinner M, Advani R, Voorhees T, Snow A, Grover N, Ayers A, Romancik J, Liu Y, Huntington S, Chavez J, Saeed H, Lazaryan A, Raghunathan V, Spurgeon S, Ollila T, Del Prete C, Olszewski A, Ayers E, Landsburg D, Echalier B, Lee J, Kamdar M, Caimi P, Fu T, Liu J, David K, Alharthy H, Law J, Karmali R, Shah H, Stephens D, Major A, Rojek A, Smith S, Yellala A, Kallam A, Nakhoda S, Khan N, Cohen J, Portell C. CNS Prophylaxis during Front-Line Therapy in Aggressive Non-Hodgkin Lymphomas: Real-World Outcomes and Practice Patterns from 19 US Academic Institutions. Blood 2020, 136: 27-28. DOI: 10.1182/blood-2020-134798.
- Worldwide Examination of Patients with CLL Hospitalized for COVID-19Roeker L, Scarfo L, Chatzikonstantinou T, Abrisqueta P, Eyre T, Cordoba R, Muntañola Prat A, Villacampa G, Leslie L, Koropsak M, Quaresmini G, Allan J, Furman R, Bhavsar E, Pagel J, Hernandez-Rivas J, Patel K, Motta M, Bailey N, Miras F, Lamanna N, Alonso R, Osorio-Prendes S, Vitale C, Kamdar M, Baltasar P, Österborg A, Hanson L, Baile M, Rodríguez-Hernández I, Valenciano S, Popov V, Barez Garcia A, Alfayate A, Oliveira A, Eichhorst B, Quaglia F, Reda G, Lopez Jimenez J, Varettoni M, Marchetti M, Romero P, Riaza Grau R, Munir T, Zabalza A, Janssens A, Niemann C, Perini G, Delgado J, Yanez San Segundo L, Gómez Roncero M, Wilson M, Patten P, Marasca R, Iyengar S, Seddon A, Torres A, Ferrari A, Cuéllar-García C, Wojenski D, El-Sharkawi D, Itchaki G, Parry H, Mateos-Mazón J, Martinez-Calle N, Ma S, Naya D, Van Der Spek E, Seymour E, Gimeno Vázquez E, Rigolin G, Mauro F, Walter H, Labrador J, De Paoli L, Laurenti L, Ruiz E, Levin M, Šimkovič M, Špaček M, Andreu R, Walewska R, Perez-Gonzalez S, Sundaram S, Wiestner A, Cuesta A, Broom A, Kater A, Muiña B, Velasquez C, Ujjani C, Seri C, Antic D, Bron D, Vandenberghe E, Chong E, Lista E, García F, Del Poeta G, Ahn I, Pu J, Brown J, Soler Campos J, Malerba L, Trentin L, Orsucci L, Farina L, Villalon L, Vidal M, Sanchez M, Terol M, De Paolis M, Gentile M, Davids M, Shadman M, Yassin M, Foglietta M, Jaksic O, Sportoletti P, Barr P, Ramos R, Santiago R, Ruchlemer R, Kersting S, Huntington S, Herold T, Herishanu Y, Thompson M, Lebowitz S, Ryan C, Jacobs R, Portell C, Isaac K, Rambaldi A, Nabhan C, Brander D, Montserrat E, Rossi G, Garcia-Marco J, Coscia M, Malakhov N, Fernandez-Escalada N, Skånland S, Coombs C, Ghione P, Schuster S, Foà R, Cuneo A, Bosch F, Stamatopoulos K, Ghia P, Mato A, Patel M. Worldwide Examination of Patients with CLL Hospitalized for COVID-19. Blood 2020, 136: 45-49. PMCID: PMC8330255, DOI: 10.1182/blood-2020-136408.
- Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia.Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.
- Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies.Davidoff A, Long J, Huntington S. Multiple myeloma (MM) therapy within a Medicare-insured patient population: Role of care setting and oncologist sub-specialization in hematologic malignancies. Journal Of Clinical Oncology 2020, 38: 38-38. DOI: 10.1200/jco.2020.38.29_suppl.38.
- Outcomes of COVID-19 in patients with CLL: a multicenter international experienceMato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, Patel K, Osterborg A, Wojenski D, Kamdar M, Huntington SF, Davids MS, Brown JR, Antic D, Jacobs R, Ahn IE, Pu J, Isaac KM, Barr PM, Ujjani CS, Geyer MB, Berman E, Zelenetz AD, Malakhov N, Furman RR, Koropsak M, Bailey N, Hanson L, Perini GF, Ma S, Ryan CE, Wiestner A, Portell CA, Shadman M, Chong EA, Brander DM, Sundaram S, Seddon AN, Seymour E, Patel M, Martinez-Calle N, Munir T, Walewska R, Broom A, Walter H, El-Sharkawi D, Parry H, Wilson MR, Patten PEM, Hernández-Rivas JÁ, Miras F, Fernández Escalada N, Ghione P, Nabhan C, Lebowitz S, Bhavsar E, López-Jiménez J, Naya D, Garcia-Marco JA, Skånland SS, Cordoba R, Eyre TA. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood 2020, 136: 1134-1143. PMID: 32688395, PMCID: PMC7472711, DOI: 10.1182/blood.2020006965.
- Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphomaPatel KK, Isufi I, Kothari S, Foss F, Huntington S. Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. Leukemia & Lymphoma 2020, 61: 3387-3394. PMID: 32835553, DOI: 10.1080/10428194.2020.1808208.
- Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysisGiri S, Aryal MR, Yu H, Grimshaw A, Pathak R, Huntington SP, Dhakal B. Efficacy and safety of frontline regimens for older transplant-ineligible patients with multiple myeloma: A systematic review and meta-analysis. Journal Of Geriatric Oncology 2020, 11: 1285-1292. PMID: 32513568, PMCID: PMC8721742, DOI: 10.1016/j.jgo.2020.05.013.
- Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agentsGiri S, Huntington SF, Wang R, Zeidan AM, Podoltsev N, Gore SD, Ma X, Gross CP, Davidoff AJ, Neparidze N. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents. Blood Advances 2020, 4: 2245-2253. PMID: 32442299, PMCID: PMC7252537, DOI: 10.1182/bloodadvances.2019001425.
- Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United StatesZeidan AM, Wang R, Wang X, Shallis RM, Podoltsev NA, Bewersdorf JP, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X. Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. Blood Advances 2020, 4: 2192-2201. PMID: 32433746, PMCID: PMC7252544, DOI: 10.1182/bloodadvances.2020001779.
- Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status.Davidoff A, Long J, Bewersdorf J, Shallis R, Zeidan A, Podoltsev N, Wang R, Gore S, Giri S, Neparidze N, Huntington S. Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status. Journal Of Clinical Oncology 2020, 38: e19057-e19057. DOI: 10.1200/jco.2020.38.15_suppl.e19057.
- PCN234 TREATMENT PATTERNS OF FOLLICULAR LYMPHOMA PATIENTS: A CLAIMS ANALYSISAppukkuttan S, Wang W, Babajanyan S, Hopson S, Du Y, Huntington S. PCN234 TREATMENT PATTERNS OF FOLLICULAR LYMPHOMA PATIENTS: A CLAIMS ANALYSIS. Value In Health 2020, 23: s64. DOI: 10.1016/j.jval.2020.04.1705.
- Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United StatesZeidan AM, Podoltsev NA, Wang X, Zhang C, Bewersdorf JP, Shallis RM, Huntington SF, Neparidze N, Giri S, Gore SD, Davidoff AJ, Ma X, Wang R. Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States. Blood Advances 2020, 4: 1615-1623. PMID: 32311013, PMCID: PMC7189301, DOI: 10.1182/bloodadvances.2020001728.
- Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved CaregiversHenckel C, Revette A, Huntington SF, Tulsky JA, Abel GA, Odejide OO. Perspectives Regarding Hospice Services and Transfusion Access: Focus Groups With Blood Cancer Patients and Bereaved Caregivers. Journal Of Pain And Symptom Management 2020, 59: 1195-1203.e4. PMID: 31926969, PMCID: PMC7239741, DOI: 10.1016/j.jpainsymman.2019.12.373.
- Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†Davidoff AJ, Hu X, Bewersdorf JP, Wang R, Podoltsev NA, Huntington SF, Gore SD, Ma X, Zeidan AM. Hypomethylating agent (HMA) therapy use and survival in older adults with Refractory Anemia with Excess Blasts (RAEB) in the United States (USA): a large propensity score-matched population-based study†. Leukemia & Lymphoma 2019, 61: 1178-1187. PMID: 31878809, PMCID: PMC7735409, DOI: 10.1080/10428194.2019.1703970.
- Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment.Huntington SF. Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment. Hematology 2019, 2019: 252-259. PMID: 31808838, PMCID: PMC6913455, DOI: 10.1182/hematology.2019000030.
- Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.Huntington SF, Davidoff AJ, Gross CP. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs. Journal Of Clinical Oncology 2019, 38: 351-358. PMID: 31804866, DOI: 10.1200/jco.19.01573.
- Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center ExperienceBewersdorf J, Shallis R, Gowda L, Hager K, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Clinical Outcomes of Patients (pts) with TP53-Mutated Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS): A Single Center Experience. Blood 2019, 134: 5173-5173. DOI: 10.1182/blood-2019-127162.
- Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought?Bewersdorf J, Shallis R, Diadamo A, Gowda L, Podoltsev N, Gore S, Prebet T, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Siddon A, Zeidan A. Isolated Trisomy 11 in Patients with Myeloid Malignancies - Is the Prognosis Not As Grim As Previously Thought? Blood 2019, 134: 5174-5174. DOI: 10.1182/blood-2019-127277.
- Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center ExperienceShallis R, Bewersdorf J, Gowda L, Podoltsev N, Prebet T, Gore S, Halene S, Isufi I, Foss F, Huntington S, Kim T, Pillai M, Parker T, Neparidze N, Bar N, Seropian S, Zeidan A. Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience. Blood 2019, 134: 1330-1330. DOI: 10.1182/blood-2019-127422.
- The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential ThrombocythemiaPodoltsev N, Wang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X. The Impact of the 2011 European Leukemianet (ELN) Guidelines for Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms on Therapeutic Phlebotomy and Hydroxyurea Use in Patients with Polycythemia Vera and Essential Thrombocythemia. Blood 2019, 134: 2125-2125. DOI: 10.1182/blood-2019-127563.
- Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US)Wang X, Wang R, Zhang C, Zeidan A, Podoltsev N, Huntington S, Gore S, Davidoff A, Ma X. Clinical Effectiveness of Hypomethylating Agents (HMAs) and Lenalidomide (Len) in Older Patients (pts) with Refractory Anemia with Ring Sideroblasts: A Large Population-Based Study in the United States (US). Blood 2019, 134: 4748-4748. DOI: 10.1182/blood-2019-128821.
- Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based StudyZeidan A, Podoltsev N, Wang X, Bewersdorf J, Shallis R, Huntington S, Neparidze N, Giri S, Gore S, Ma X, Davidoff A, Wang R. Patterns of Care and Clinical Outcomes with 7+3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study. Blood 2019, 134: 116-116. DOI: 10.1182/blood-2019-126643.
- Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United StatesZeidan A, Wang R, Wang X, Shallis R, Podoltsev N, Bewersdorf J, Huntington S, Neparidze N, Giri S, Gore S, Davidoff A, Ma X. Clinical Outcomes of Older Patients (pts) with Acute Myeloid Leukemia (AML) Receiving Hypomethylating Agents (HMAs): A Large Population-Based Study in the United States. Blood 2019, 134: 646-646. DOI: 10.1182/blood-2019-127398.
- Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with HydroxyureaWang R, Shallis R, Huntington S, Zeidan A, Gore S, Davidoff A, Ma X, Podoltsev N. Incidence and Risk Factors of Second Malignancies Among Medicare Beneficiaries with Newly-Diagnosed Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms Receiving Cytoreductive Therapy with Hydroxyurea. Blood 2019, 134: 330-330. DOI: 10.1182/blood-2019-127568.
- AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical StudyHuntington S, Kallam A, Basile F, Ulanet D, Xu H, Yin F, Mobilia M, Cooper M, Shah B, Leonard J, von Keudell G, Gopal A. AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study. Blood 2019, 134: 1286-1286. DOI: 10.1182/blood-2019-123420.
- Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)Abrisqueta P, Sancho J, Cordoba R, Persky D, Andreadis C, Huntington S, Carpio C, Morillo Giles D, Wei X, Li Y, Zuraek M, Burgess M, Hege K, Martín A. Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL). Blood 2019, 134: 4089-4089. DOI: 10.1182/blood-2019-125310.
- Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell TransplantationChandhok N, Huntington S, Isufi I, Gowda L, Xu M, Bar N, Seropian S, Foss F. Peripheral Blood Involvement By Flow Cytometry As a Prognostic Factor in Aggressive T Cell Lymphomas Following Autologous Stem Cell Transplantation. Blood 2019, 134: 4055-4055. DOI: 10.1182/blood-2019-128888.
- Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled TrialsGiri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188-2188. DOI: 10.1182/blood-2019-130389.
- Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United StatesHuntington S, Soulos P, Barr P, Jacobs R, Lansigan F, Odejide O, Schwartzberg L, Davidoff A, Gross C. Utilization and Early Discontinuation of First-Line Ibrutinib for Patients with Chronic Lymphocytic Leukemia Treated in the Community Oncology Setting in the United States. Blood 2019, 134: 797-797. DOI: 10.1182/blood-2019-122054.
- A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell LymphomasMato A, Schuster S, Foss F, Isufi I, Ding W, Brander D, Sitlinger A, Tun H, Alhaj Moustafa M, Kennard K, King C, Koehler A, Aitken C, He W, Kearney A, Gui M, Anderson B, Rosenthal A, Roeker L, Huntington S. A Phase Ia/Ib Study Exploring the Synthetic Lethality of the Orally Administered Novel BTK Inhibitor, Dtrmwxhs-12 (DTRM-12), in Combination with Everolimus and Pomalidomide in Patients with Relapsed/Refractory CLL, DLBCL or Other B-Cell Lymphomas. Blood 2019, 134: 810-810. DOI: 10.1182/blood-2019-126192.
- Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agentsZeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leukemia & Lymphoma 2019, 61: 397-408. PMID: 31570040, PMCID: PMC7732188, DOI: 10.1080/10428194.2019.1663423.
- Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma.Huntington SF, Hoag JR, Wang R, Zeidan AM, Giri S, Gore SD, Ma X, Gross CP, Davidoff AJ. Physician Experience and Risk of Rituximab Discontinuation in Older Adults With Non-Hodgkin's Lymphoma. Journal Of The National Comprehensive Cancer Network 2019, 17: 1194-1202. PMID: 31590152, DOI: 10.6004/jnccn.2019.7314.
- Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysisZeidan AM, Podoltsev NA, Wang X, Bewersdorf JP, Shallis RM, Huntington SF, Gore SD, Davidoff AJ, Ma X, Wang R. Temporal patterns and predictors of receiving no active treatment among older patients with acute myeloid leukemia in the United States: A population‐level analysis. Cancer 2019, 125: 4241-4251. PMID: 31483484, PMCID: PMC7733320, DOI: 10.1002/cncr.32439.
- Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United StatesGiri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore SD, Neparidze N, Ma X, Gross CP, Davidoff AJ, Huntington SF. Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States. Cancer 2019, 125: 4084-4095. PMID: 31381151, DOI: 10.1002/cncr.32428.
- Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung CancerGiri S, Huntington SF. Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non–Small Cell Lung Cancer. JAMA Oncology 2019, 5: 1066-1066. PMID: 31095252, DOI: 10.1001/jamaoncol.2019.1088.
- Healthcare expenses for treatment of acute myeloid leukemiaBewersdorf JP, Shallis R, Wang R, Huntington S, Perreault S, Ma X, Zeidan AM. Healthcare expenses for treatment of acute myeloid leukemia. Expert Review Of Hematology 2019, 12: 641-650. PMID: 31159602, DOI: 10.1080/17474086.2019.1627869.
- RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysisZeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leukemia & Lymphoma 2019, 60: 3181-3187. PMID: 31170846, DOI: 10.1080/10428194.2019.1622700.
- Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.
- Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin LymphomaHuntington SF, Zhu W, Hoag JR, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma. JNCI Cancer Spectrum 2019, 3: pkz030. PMID: 31360905, PMCID: PMC6649837, DOI: 10.1093/jncics/pkz030.
- PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATESHuntington S, Strunz-McKendry T, Masaquel A, Shapouri S, Sail K, Durno N, Mato A. PCN122 COST-EFFECTIVENESS OF A 24-MONTH FIXED DURATION OF VENETOCLAX IN COMBINATION WITH RITUXIMAB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED STATES. Value In Health 2019, 22: s78-s79. DOI: 10.1016/j.jval.2019.04.246.
- Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.Podoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia. Journal Of The National Comprehensive Cancer Network 2019, 17: 211-219. PMID: 30865915, DOI: 10.6004/jnccn.2018.7095.
- Reply to H.J.A. Adams et alHuntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Reply to H.J.A. Adams et al. Journal Of Clinical Oncology 2019, 37: jco.18.02297. PMID: 30742563, DOI: 10.1200/jco.18.02297.
- Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective AnalysisBair SM, Strelec LE, Feldman TA, Ahmed G, Armand P, Shah NN, Singavi AN, Reddy N, Khan N, Andreadis C, Vu K, Huntington SF, Giri S, Ujjani C, Howlett C, Faheem M, Youngman MR, Nasta SD, Landsburg DJ, Schuster SJ, Svoboda J. Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis. The Oncologist 2018, 24: 955-962. PMID: 30568021, PMCID: PMC6656463, DOI: 10.1634/theoncologist.2018-0538.
- Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based AnalysisZeidan A, Hu X, Zhu W, Stahl M, Giri S, Huntington S, Wang R, Podoltsev N, Gore S, Ma X, Davidoff A. Does Provider Experience Treating Patients (pts) with Myelodysplastic Syndromes (MDS) Explain Duration of Hypomethylating Agent (HMA) Therapy and Overall Survival (OS)? A Large Population-Based Analysis. Blood 2018, 132: 370-370. DOI: 10.1182/blood-2018-99-111052.
- Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET UtilityHuntington S, Zhu W, Hoag J, Wang R, Zeidan A, Giri S, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A. Association between Oncologist Ownership of Imaging Facilities and Utilization: An Analysis of Positron-Emission Tomography (PET) Use in Lymphoma Settings with Variable PET Utility. Blood 2018, 132: 3538-3538. DOI: 10.1182/blood-2018-99-115140.
- Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) TransfusionsZeidan A, Zhu W, Wang R, Stahl M, Huntington S, Giri S, Podoltsev N, Gore S, Ma X, Davidoff A. Transfusion Independence in Lower-Risk, Non-del5(q) Myelodysplastic Syndromes (LR-MDS) Among Patients (pts) Initiating Hypomethylating Agents (HMAs) While Receiving Red Blood Cell (RBC) Transfusions. Blood 2018, 132: 838-838. DOI: 10.1182/blood-2018-99-116497.
- Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based StudyPodoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Huntington S, Giri S, Davidoff A, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Essential Thrombocythemia: A Population-Based Study. Blood 2018, 132: 4865-4865. DOI: 10.1182/blood-2018-99-119118.
- Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based StudyPodoltsev N, Zhu M, Wang R, Zeidan A, Wang X, Davidoff A, Huntington S, Giri S, Gore S, Ma X. Use of Statins, Survival and Incidence of Thrombosis Among Older Adults with Polycythemia Vera: A Population-Based Study. Blood 2018, 132: 3580-3580. DOI: 10.1182/blood-2018-99-119272.
- Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United StatesGiri S, Zhu W, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Davidoff A, Huntington S. Racial Disparities in the Utilization of Recommended Supportive Care Among Patients with Multiple Myeloma in the United States. Blood 2018, 132: 978-978. DOI: 10.1182/blood-2018-99-119791.
- Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic LethalityHuntington S, Schuster S, He W, Shen T, Walker H, Leary L, Boyhen K, Gill J, Chatburn E, Kennard K, Dwivedy Nasta S, Landsburg D, Porter D, Napier E, Hughes M, Latorre T, Walsh K, Dorsey C, Svoboda J, Addis V, Anderson B, Leblond E, Song Y, Zhu J, Deng L, Brander D, Ding W, Rosenthal A, Tun H, Mato A. Phase I Study of First-in-Class Oral Triplet Therapy DTRM-555 in Relapsed/Refractory Lymphoma Patients through Fixed-Dose Combination and Synthetic Lethality. Blood 2018, 132: 5384-5384. DOI: 10.1182/blood-2018-99-112944.
- The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia veraPodoltsev NA, Zhu M, Zeidan AM, Wang R, Wang X, Davidoff AJ, Huntington SF, Giri S, Gore SD, Ma X. The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera. Blood Advances 2018, 2: 2681-2690. PMID: 30333100, PMCID: PMC6199652, DOI: 10.1182/bloodadvances.2018021436.
- Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin LymphomaHuntington SF, von Keudell G, Davidoff AJ, Gross CP, Prasad SA. Cost-Effectiveness Analysis of Brentuximab Vedotin With Chemotherapy in Newly Diagnosed Stage III and IV Hodgkin Lymphoma. Journal Of Clinical Oncology 2018, 36: jco.18.00122. PMID: 30285558, PMCID: PMC6241679, DOI: 10.1200/jco.18.00122.
- Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphomaHuntington SF, Hoag JR, Zhu W, Wang R, Zeidan AM, Giri S, Podoltsev NA, Gore SD, Ma X, Gross CP, Davidoff AJ. Oncologist volume and outcomes in older adults diagnosed with diffuse large B cell lymphoma. Cancer 2018, 124: 4211-4220. PMID: 30216436, PMCID: PMC6263848, DOI: 10.1002/cncr.31688.
- Costs of relapsed diffuse large B-cell lymphoma among Medicare patientsHuntington S, Keshishian A, McGuire M, Xie L, Baser O. Costs of relapsed diffuse large B-cell lymphoma among Medicare patients. Leukemia & Lymphoma 2018, 59: 2880-2887. PMID: 29936866, DOI: 10.1080/10428194.2018.1459613.
- Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer Journal 2018, 8: 55. PMID: 29891916, PMCID: PMC5995881, DOI: 10.1038/s41408-018-0081-8.
- Prognostic understanding in acute leukemia: Patient-physician differences.Shimer S, Canavan M, Capasso R, Gore S, Tannenbaum S, Babar T, Podoltsev N, Seropian S, Huntington S, Zeidan A, von Keudell G, Prebet T, Adelson K. Prognostic understanding in acute leukemia: Patient-physician differences. Journal Of Clinical Oncology 2018, 36: e22124-e22124. DOI: 10.1200/jco.2018.36.15_suppl.e22124.
- Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma.Huntington S, Von Keudell G, Davidoff A, Gross C, Prasad S. Cost-effectiveness analysis of brentuximab vedotin with chemotherapy in newly diagnosed stage III/IV Hodgkin lymphoma. Journal Of Clinical Oncology 2018, 36: 6609-6609. DOI: 10.1200/jco.2018.36.15_suppl.6609.
- Impact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline.Konuthula D, Canavan M, Huntington S, Strait M, Vega T, Framski K, Adelson K. Impact of electronic decision support and targeted educational intervention to increase adherence with ASCO Choosing Wisely breast cancer staging guideline. Journal Of Clinical Oncology 2018, 36: e18826-e18826. DOI: 10.1200/jco.2018.36.15_suppl.e18826.
- Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States.Giri S, Mehta K, Hoag J, Huntington S, Dhakal B. Trends in utilization and in-hospital outcomes of high dose therapy and autologous stem cell transplantation among patients with AL amyloidosis in the United States. Journal Of Clinical Oncology 2018, 36: e20000-e20000. DOI: 10.1200/jco.2018.36.15_suppl.e20000.
- The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013Tsai DE, Bagley S, Reshef R, Shaked A, Bloom RD, Ahya V, Goldberg L, Chung A, Debonera F, Schuster SJ, Huntington SF. The changing face of adult posttransplant lymphoproliferative disorder: Changes in histology between 1999 and 2013. American Journal Of Hematology 2018, 93: 874-881. PMID: 29659047, DOI: 10.1002/ajh.25116.
- Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents eraMato A, Jahnke J, Li P, Mehra M, Ladage VP, Mahler M, Huntington S, Doshi JA. Real-world treatment and outcomes among older adults with chronic lymphocytic leukemia before the novel agents era. Haematologica 2018, 103: e462-e465. PMID: 29700170, PMCID: PMC6165790, DOI: 10.3324/haematol.2017.185868.
- R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysisShah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach AE, Costa LJ, Xavier AC, Okal R, Kanate AS, Ghosh N, Kharfan‐Dabaja M, Strelec L, Hamadani M, Fenske TS, Calzada O, Cohen JB, Chavez J, Svoboda J. R‐CHOP versus dose‐adjusted R‐EPOCH in frontline management of primary mediastinal B‐cell lymphoma: a multi‐centre analysis. British Journal Of Haematology 2017, 180: 534-544. PMID: 29265182, DOI: 10.1111/bjh.15051.
- Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation.Zeidan AM, Stahl M, Hu X, Wang R, Huntington SF, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Long-term survival of older patients with MDS treated with HMA therapy without subsequent stem cell transplantation. Blood 2017, 131: 818-821. PMID: 29259002, PMCID: PMC6410557, DOI: 10.1182/blood-2017-10-811729.
- Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United StatesGiri S, Pathak R, Franklin R, Podoltsev N, Huntington S, Mehta K, Zeidan A. Relationship between Hospital Volume and Inpatient Mortality Among Patients Diagnosed with Thrombotic Thrombocytopenic Purpura (TTP) in the United States. Blood 2017, 130: 675-675. DOI: 10.1182/blood.v130.suppl_1.675.675.
- Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based studyZeidan AM, Long JB, Wang R, Hu X, Yu JB, Huntington SF, Abel GA, Mougalian SS, Podoltsev NA, Gore SD, Gross CP, Ma X, Davidoff AJ. Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study. PLOS ONE 2017, 12: e0184747. PMID: 28902882, PMCID: PMC5597231, DOI: 10.1371/journal.pone.0184747.
- Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of LifeWang R, Zeidan AM, Halene S, Xu X, Davidoff AJ, Huntington SF, Podoltsev NA, Gross CP, Gore SD, Ma X. Health Care Use by Older Adults With Acute Myeloid Leukemia at the End of Life. Journal Of Clinical Oncology 2017, 35: jco.2017.72.714. PMID: 28783450, PMCID: PMC5648174, DOI: 10.1200/jco.2017.72.7149.
- Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantationHui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123: 3763-3771. PMID: 28640385, PMCID: PMC5610636, DOI: 10.1002/cncr.30818.
- Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based studyZeidan AM, Hu X, Long JB, Wang R, Ma X, Podoltsev NA, Huntington SF, Gore SD, Davidoff AJ. Hypomethylating agent therapy use and survival in older patients with chronic myelomonocytic leukemia in the United States: A large population‐based study. Cancer 2017, 123: 3754-3762. PMID: 28621841, PMCID: PMC6540984, DOI: 10.1002/cncr.30814.
- Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study.Zeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. Hypomethylating agent (HMA) therapy use and survival in older patients with higher risk myelodysplastic syndromes (HR-MDS) in the United States (USA): A large population-based study. Journal Of Clinical Oncology 2017, 35: 7057-7057. DOI: 10.1200/jco.2017.35.15_suppl.7057.
- Physician volume and discontinuation of rituximab during lymphoma treatment.Huntington S, Long J, Hoag J, Wang R, Zeidan A, Giri S, Gore S, Ma X, Gross C, Davidoff A. Physician volume and discontinuation of rituximab during lymphoma treatment. Journal Of Clinical Oncology 2017, 35: 6593-6593. DOI: 10.1200/jco.2017.35.15_suppl.6593.
- 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Giri S, Stahl M, Gore S, Ma X, Davidoff A. 121 Hypomethylating Agent Therapy Use and Survival in Older Patients with Higher Risk Myelodysplastic Syndromes in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s75-s76. DOI: 10.1016/s0145-2126(17)30234-5.
- 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Ma X, Podoltsev N, Huntington S, Gore S, Davidoff A. 32 Hypomethylating Agent Therapy use and Survival in Older Patients with Chronic Myelomonocytic Leukemia in USA: A Large Population-Based Study. Leukemia Research 2017, 55: s20-s21. DOI: 10.1016/s0145-2126(17)30145-5.
- Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based StudyZeidan A, Hu X, Long J, Wang R, Huntington S, Podoltsev N, Gore S, Ma X, Davidoff A. Hypomethylating Agent Therapy and Survival Among Older Patients with Chronic Myelomonocytic Leukemia in the United States: A Large Population-Based Study. Blood 2016, 128: 394-394. DOI: 10.1182/blood.v128.22.394.394.
- Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell RescueHui L, von Keudell G, Wang R, Zeidan A, Gore S, Ma X, Davidoff A, Huntington S. Cost-Effectiveness Analysis of Consolidation with Brentuximab Vendotin Versus Active Surveillance in Individuals with High-Risk Hodgkin Lymphoma Undergoing High Dose Chemotherapy with Stem Cell Rescue. Blood 2016, 128: 1188-1188. DOI: 10.1182/blood.v128.22.1188.1188.
- Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare PopulationHuntington S, Keshishian A, Xie L, Baser O, McGuire M. Evaluating the Economic Burden and Health Care Utilization Following First-Line Therapy for Diffuse Large B-Cell Lymphoma Patients in the US Medicare Population. Blood 2016, 128: 3574-3574. DOI: 10.1182/blood.v128.22.3574.3574.
- Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare DatabaseMato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Fanning M, Doshi J, Huntington S. Characterization of Real World Survival Outcomes Among Older Adults with Chronic Lymphocytic Leukemia Receiving Second Line Treatment in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4790-4790. DOI: 10.1182/blood.v128.22.4790.4790.
- Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare DatabaseMato A, Jahnke J, Li P, Mehra M, Ladage V, Mahler M, Huntington S, Doshi J. Characterization of Real World Treatment Patterns and Outcomes Among Older Adults with Chronic Lymphocytic Leukemia in the Pre Novel-Agents Era: An Analysis of the 2007-2013 SEER-Medicare Database. Blood 2016, 128: 4773-4773. DOI: 10.1182/blood.v128.22.4773.4773.
- Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based StudyWang R, Zeidan AM, Yu JB, Soulos PR, Davidoff AJ, Gore SD, Huntington SF, Gross CP, Ma X. Myelodysplastic Syndromes and Acute Myeloid Leukemia After Radiotherapy for Prostate Cancer: A Population‐Based Study. The Prostate 2016, 77: 437-445. PMID: 27868212, PMCID: PMC5785924, DOI: 10.1002/pros.23281.
- High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part DHuntington SF, Davidoff AJ. High-Cost, High-Value Oral Specialty Drugs: More Evidence on the Impact of Cost Sharing in Medicare Part D. Journal Of Clinical Oncology 2016, 34: 4307-4309. PMID: 27998230, DOI: 10.1200/jco.2016.70.2738.
- Cancer-related financial toxicity: beyond the realm of drug pricing and out-of-pocket costsHuntington SF. Cancer-related financial toxicity: beyond the realm of drug pricing and out-of-pocket costs. Annals Of Oncology 2016, 27: 2143-2145. PMID: 27742653, DOI: 10.1093/annonc/mdw540.
- Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromesZeidan AM, Davidoff AJ, Long JB, Hu X, Wang R, Ma X, Gross CP, Abel GA, Huntington SF, Podoltsev NA, Hajime U, Prebet T, Gore SD. Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes. British Journal Of Haematology 2016, 175: 829-840. PMID: 27650975, DOI: 10.1111/bjh.14305.
- Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United StatesZeidan AM, Wang R, Gross CP, Gore SD, Huntington SF, Prebet T, Abel GA, Davidoff AJ, Ma X. Modest improvement in survival of patients with refractory anemia with excess blasts in the hypomethylating agents era in the United States. Leukemia & Lymphoma 2016, 58: 982-985. PMID: 27558206, DOI: 10.1080/10428194.2016.1214954.
- Platelet Disorders: Diagnostic Tests and Their InterpretationsHuntington S, O’Hara M, Bennett J. Platelet Disorders: Diagnostic Tests and Their Interpretations. 2016, 171-183. DOI: 10.1007/978-3-319-30352-9_16.
- Negative Studies in Cancer Research: Why the Negativity?Huntington SF, Gross CP. Negative Studies in Cancer Research: Why the Negativity? JAMA Oncology 2016, 2: 865-6. PMID: 26967116, DOI: 10.1001/jamaoncol.2015.6540.
- ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia PatientsDoshi J, Li P, Huo H, Pettit A, Kumar R, Huntington S, Weiss B. ME2 Medicare Part D Cost Sharing And Specialty Drug Initiation In Newly Diagnosed Chronic Myeloid Leukemia Patients. Value In Health 2016, 19: a3. DOI: 10.1016/j.jval.2016.03.035.
- High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.Doshi JA, Li P, Huo H, Pettit AR, Kumar R, Weiss BM, Huntington SF. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia. The American Journal Of Managed Care 2016, 22: s78-86. PMID: 27270157.
- Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS)Zeidan A, Long J, Hall J, Wang R, Huntington S, Abel G, Prebet T, Podoltsev N, Gross C, Gore S, Ma X, Davidoff A. Comparative Effectiveness of Azacitidine Versus Decitabine Among Older Adults Diagnosed with Higher-Risk Myelodysplastic Syndromes (HR-MDS). Blood 2015, 126: 3285-3285. DOI: 10.1182/blood.v126.23.3285.3285.
- Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US)Zeidan A, Wang R, Davidoff A, Gore S, Soulos P, Huntington S, Gross C, Ma X. Lack of Association Between Costs of Care and Overall Survival (OS) Among Medicare Beneficiaries with Myelodysplastic Syndromes (MDS) in the United States (US). Blood 2015, 126: 873-873. DOI: 10.1182/blood.v126.23.873.873.
- Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyHuntington SF, Weiss BM, Vogl DT, Cohen AD, Garfall AL, Mangan PA, Doshi JA, Stadtmauer EA. Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot study. The Lancet Haematology 2015, 2: e408-e416. PMID: 26686042, DOI: 10.1016/s2352-3026(15)00151-9.
- Abstract 3430: Toxicity and long-term outcomes of elderly patients with refractory or relapsed diffuse large B cell lymphoma undergoing autologous stem cell transplantationHuntington S, Hu B, Landsburg D, Mato A, Nasta S, Schuster S, Stadtmauer E, Svoboda J. Abstract 3430: Toxicity and long-term outcomes of elderly patients with refractory or relapsed diffuse large B cell lymphoma undergoing autologous stem cell transplantation. 2015, 3430-3430. DOI: 10.1158/1538-7445.am2015-3430.
- Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cellsEvans AG, Rothberg PG, Burack WR, Huntington SF, Porter DL, Friedberg JW, Liesveld JL. Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells. British Journal Of Haematology 2015, 171: 205-209. PMID: 26084925, DOI: 10.1111/bjh.13562.
- Assessing financial toxicity in insured patients with multiple myeloma.Huntington S, Weiss B, Vogl D, Cohen A, Garfall A, Doshi J, Stadtmauer E. Assessing financial toxicity in insured patients with multiple myeloma. Journal Of Clinical Oncology 2015, 33: 6600-6600. DOI: 10.1200/jco.2015.33.15_suppl.6600.
- A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas.Svoboda J, Strelec L, Shah N, Chong E, Montrey K, Walsh K, Huntington S, Mato A, Landsburg D, Nasta S, Schuster S. A phase I trial of lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with high-risk relapsed/refractory lymphomas. Journal Of Clinical Oncology 2015, 33: 8553-8553. DOI: 10.1200/jco.2015.33.15_suppl.8553.
- Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First RemissionHuntington SF, Svoboda J, Doshi JA. Cost-Effectiveness Analysis of Routine Surveillance Imaging of Patients With Diffuse Large B-Cell Lymphoma in First Remission. Journal Of Clinical Oncology 2015, 33: 1467-1474. PMID: 25823735, DOI: 10.1200/jco.2014.58.5729.
- Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphomaHuntington SF, Nasta SD, Schuster SJ, Doshi JA, Svoboda J. Utility of interim and end-of-treatment [18F]-fluorodeoxyglucose positron emission tomography–computed tomography in frontline therapy of patients with diffuse large B-cell lymphoma. Leukemia & Lymphoma 2015, 56: 2579-2584. PMID: 25629993, DOI: 10.3109/10428194.2015.1007506.
- The Impact of Marital and Socioeconomic Status on Outcomes of Patients with Acute Promyelocytic LeukemiaHuntington S, Shah N, Epstein A, Loren A. The Impact of Marital and Socioeconomic Status on Outcomes of Patients with Acute Promyelocytic Leukemia. Blood 2014, 124: 1282-1282. DOI: 10.1182/blood.v124.21.1282.1282.
- Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma.Huntington S, Svoboda J, Doshi J. Cost-utility analysis of routine surveillance imaging of patients in first remission after treatment for diffuse large B-cell lymphoma. Journal Of Clinical Oncology 2014, 32: 6526-6526. DOI: 10.1200/jco.2014.32.15_suppl.6526.
- Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL).Huntington S, Nasta S, Schuster S, Doshi J, Svoboda J. Utility assessment of interim FDG-PET/CT in frontline therapy of patients with diffuse large B-cell lymphoma (DLBCL). Journal Of Clinical Oncology 2014, 32: 8549-8549. DOI: 10.1200/jco.2014.32.15_suppl.8549.
- Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapyHuntington SF, Talbott MS, Greer JP, Morgan DS, Reddy N. Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy. Leukemia & Lymphoma 2012, 53: 1461-1468. PMID: 22260160, PMCID: PMC7845767, DOI: 10.3109/10428194.2012.658793.
- Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP TherapyHuntington S, Sharifi M, Greer J, Morgan D, Reddy N. Toxicity and Response Among Octogenarians and Nonagenarians with Diffuse Large B Cell Lymphoma Treated with Rituximab-CHOP Therapy. Blood 2010, 116: 1778-1778. DOI: 10.1182/blood.v116.21.1778.1778.